Science & technology
Our pipeline
Seasonal influenza

Investigational influenza (qNIV) vaccine

Seasonal influenza Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
Seasonal influenza
 
Phase 2
Matrix-M™ adjuvant
Therapeutic area
Respiratory diseases
Infectious disease
Seasonal influenza
Status
 
Phase 2
Technology
Matrix-M™ adjuvant

About the candidate

The investigational in uenza (qNIV) vaccine is our quadrivalent nanoparticle vaccine candidate, targeting seasonal flu. qNIV is designed using our recombinant technology, with 4 forms of wild-type hemagglutinin (HA) protein from the in influenza virus as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.1

Why it matters

Seasonal influenza is a significant global burden, with up to 650,000 flu-related deaths each year around the world.2 Current influenza vaccines have several limitations.3 New vaccines may help address these limitations.

In a successful phase 3 trial in the United States, qNIV met all of its endpoints.1

Investigational influenza (qNIV) vaccine design
1
Genes inserted into insect baculovirus

Four Influenza Hemagglutinin (HA) genes (H1, H3, B-V, B-Y) are engineered into baculovirus for independent expression.

Genes inserted into insect baculovirus. Baculovirus. Hemagglutinin (HA) protein. Influenza. HA genes. Viral RNA.
2
Sf9 cells infected

Recombinant baculovirus infects moth cells in the S. frugiperda (Sf9) expression system.

Sf9 cells infected. Baculovirus. SF9 Cell.
3
DNA enters Sf9 cell nucleus

H A DNA is transcribed.

Stable recombination gene enters yeast cell nucleus. DNA. Nucleus. mRNA.
4
Sf9 cells produce proteins

HA proteins are each expressed in their native conformation.

Sf9 cells produce proteins. mRNA. Translation and maturation. HA proteins.
5
Nanoparticle formation

Proteins are harvested. Vaccine nanoparticles assemble as proteins arranged around a Polysorbate 80 (PS80) core.

Nanoparticle formation. PS80 core.
6
Final vaccine

HA vaccine nanoparticles are mixed with Matrix-M™ adjuvant to create the ready-to-use investigational vaccine.

Final vaccine. HA vaccine nanoparticles. Matrix-M adjuvant. B-Y. B-V.

Infographic displaying of the Investigational influenza (qNIV) vaccine design.

  1. Shinde V, et al. Lancet Infect Dis. Sept 2021. doi: https://doi.org/10.1016/S1473-3099(21)00192-4. [Accessed 2 Feb 2022]
  2. In uenza – estimating burden of disease. WHO. Available at: https://www.who.int/europe/health-topics/in uenza-seasonal/e stimating-disease-burden-of-in uenza#tab=tab_1 [Accessed 24 Jan 2023]
  3. Soema P, et al. Eur J Biopharm. 2015;95:251–263.
Clinical trials
More about the disease